The allure of high-tech cardiac imaging has proved strong enough to entice venture capitalists to invest $21 million in NexRay, developers of a low-dose x-ray fluoroscopy system. The fledgling product, which uses a proprietary technology called
The allure of high-tech cardiac imaging has proved strong enough to entice venture capitalists to invest $21 million in NexRay, developers of a low-dose x-ray fluoroscopy system. The fledgling product, which uses a proprietary technology called Scanning-Beam Digital X-ray, promises to deliver 3-D imaging applicable to the interventional cardiology market. NexRay, formerly Cardiac Mariners, promises improved image quality and up to 90% reduction in radiation exposure to the patient and staff.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.